Related Articles
XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second‑line setting involving the sequential administration of XELOX and XELIRI
Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer
First‑line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis
Cell‑free DNA and chemoembolization in patients with liver metastases from colorectal cancer